Thomas West, diagnostics division president of Hologic, resigned effective July 1. In a filing with the US Securities and Exchange Commission, the firm said he is leaving Hologic to assume the role of CEO at another publicly traded company.
Eric Rasmussen, Bryan Baldasare
Eric Rasmussen has resigned as executive VP and CFO of Meridian Bioscience effective June 28 in order to pursue other opportunities. Meridian has appointed Bryan Baldasare, currently the firm's senior VP, corporate controller, treasurer, and chief accounting officer, to serve as interim CFO.
Eugene Durenard, Ted Murphy
Co-Diagnostics has appointed Eugene Durenard and Ted Murphy to its board of directors, where they will serve on the compensation and corporate governance/nomination committees and audit committees as independent directors. They will be replacing Frank Kiesnar and Edward Borkowski, who resigned and retired as directors, respectively.
Durenard is the founder of Hyperbolic Holdings and has been the company's CEO since 2018, cofounder and chief innovation officer of Healthcare Impact Holdings since May 2018, cofounder and trustee of Healthcare Impact Foundation since 2017, cofounder of Global Better Health since December 2018, as well as advisor and managing director of the Stetson Family Office since September 2016. Murphy serves on the board of directors of three Canadian publicly reporting companies and has been a senior partner in a private investment firm since 1999.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.